Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

578
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Stress Prevention and Stress Management Techniques IV01:26

Stress Prevention and Stress Management Techniques IV

315
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
315
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.4K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.4K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

645
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
645

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Association between interleukin-6, suPAR, and hsCRP with subclinical left ventricular dysfunction in type 1 diabetes: The Thousand & 1 study" [Diabetes Res. Clin. Pract. 222 (2025) 112071].

Diabetes research and clinical practice·2026
Same author

Osteoarthritis pain inversely correlates with histidine and glutamine following CSF and serum profiling.

Arthritis research & therapy·2026
Same author

Acute biological age as a determinant of adverse outcomes requiring hospitalization in Danish emergency department patients.

Communications medicine·2026
Same author

Echocardiography and inflammatory biomarkers for predicting mortality and major adverse cardiovascular events in type 1 diabetes.

Cardiovascular diabetology·2026
Same author

Blood Biomarker and Raman Analysis of Leukocytes in the Multicenter Intelligence Trials: At the Intensive Care Unit (Intelligence-1) and the Emergency Department (Intelligence-2).

Shock (Augusta, Ga.)·2025
Same author

Proteomic signatures reflect effects of semaglutide treatment for MASH.

JHEP reports : innovation in hepatology·2025

Related Experiment Video

Updated: Mar 26, 2026

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
06:39

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Published on: August 28, 2017

15.0K

Plasma suPAR is lowered by smoking cessation: a randomized controlled study.

Jesper Eugen-Olsen1, Steen Ladelund1, Lars Tue Sørensen2

  • 1Clinical Research Centre, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.

European Journal of Clinical Investigation
|January 23, 2016
PubMed
Summary

Smoking cessation significantly reduces soluble urokinase plasminogen activator receptor (suPAR) levels in smokers. This inflammatory biomarker may help identify smokers who benefit most from quitting.

Keywords:
Biomarkerinflammationlifestyleprognosisrisk

More Related Videos

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

11.9K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

7.9K

Related Experiment Videos

Last Updated: Mar 26, 2026

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
06:39

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Published on: August 28, 2017

15.0K
Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

11.9K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

7.9K

Area of Science:

  • Biomarkers
  • Inflammation
  • Smoking Cessation

Background:

  • Soluble urokinase plasminogen activator receptor (suPAR) is a stable inflammatory biomarker.
  • suPAR predicts disease development and prognosis in general and smoking populations.
  • The effect of smoking cessation on suPAR levels is unknown.

Purpose of the Study:

  • To investigate the impact of smoking cessation on suPAR levels.
  • To compare suPAR changes in smokers undergoing cessation with continued smokers and non-smokers.

Main Methods:

  • Randomized controlled trial with 48 smokers into three groups: continued smoking, nicotine patch, or placebo patch.
  • Non-smokers included for comparison.
  • suPAR and C-reactive protein (CRP) levels measured by ELISA.

Main Results:

  • Smokers had significantly higher baseline suPAR levels than non-smokers.
  • Smoking cessation, with or without nicotine replacement, led to decreased suPAR levels after 4 weeks.
  • suPAR levels in former smokers were comparable to non-smokers.
  • CRP levels were unaffected by smoking status or cessation.

Conclusions:

  • Smoking cessation effectively reduces suPAR levels.
  • suPAR may serve as a personalized risk indicator for smokers, identifying those who would benefit most from quitting.
  • suPAR levels can help tailor smoking cessation interventions.